

West Nile Virus Infections - Pipeline Review, H2 2019

<https://marketpublishers.com/r/W7AE4BADEA8EN.html>

Date: November 2019

Pages: 75

Price: US\$ 2,000.00 (Single User License)

ID: W7AE4BADEA8EN

Abstracts

West Nile Virus Infections - Pipeline Review, H2 2019

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide West Nile Virus Infections - Pipeline Review, H2 2019, provides an overview of the West Nile Virus Infections (Infectious Disease) pipeline landscape.

West Nile infection is caused by a virus transmitted by mosquitoes. The West Nile virus is a type of virus known as a Flavivirus. Symptoms include a fever, headache, body aches, skin rash, and swollen lymph glands. Risk factors for developing a more severe form of West Nile virus include conditions that weaken the immune system, such as HIV, organ transplants, and recent chemotherapy, age and pregnancy.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide West Nile Virus Infections - Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for West Nile Virus Infections (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The West Nile Virus Infections (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for West Nile Virus Infections and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase

I, Preclinical, Discovery and Unknown stages are 4, 6, 2 and 1 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 4 and 3 molecules, respectively.

West Nile Virus Infections (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

The pipeline guide provides a snapshot of the global therapeutic landscape of West Nile Virus Infections (Infectious Disease).

The pipeline guide reviews pipeline therapeutics for West Nile Virus Infections (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in West Nile Virus Infections (Infectious Disease) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates West Nile Virus Infections (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for West Nile Virus Infections (Infectious Disease)

REASONS TO BUY

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for West Nile Virus Infections (Infectious Disease).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding West Nile Virus Infections (Infectious Disease) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

- Introduction
- Global Markets Direct Report Coverage
- West Nile Virus Infections - Overview
- West Nile Virus Infections - Therapeutics Development Pipeline Overview
- Pipeline by Companies
- Pipeline by Universities/Institutes
- Products under Development by Companies
- Products under Development by Universities/Institutes
- West Nile Virus Infections - Therapeutics Assessment
 - Assessment by Target
 - Assessment by Mechanism of Action
 - Assessment by Route of Administration
 - Assessment by Molecule Type
- West Nile Virus Infections - Companies Involved in Therapeutics Development
 - AIM ImmunoTech Inc
 - CEL-SCI Corp
 - Emergex Vaccines Ltd
 - Ennaid Therapeutics LLC
 - Fab'entech SA
 - Hawaii Biotech Inc
 - Imutex Ltd
 - Kineta Inc
 - Najit Technologies Inc
 - Plex Pharmaceuticals Inc
- West Nile Virus Infections - Drug Profiles
 - AGS-v - Drug Profile
 - Product Description
 - Mechanism Of Action
 - R&D Progress
 - AGS-v PLUS - Drug Profile
 - Product Description
 - Mechanism Of Action
 - R&D Progress
 - Alferon LDO - Drug Profile
 - Product Description
 - Mechanism Of Action

R&D Progress

Antisense RNAi Oligonucleotide for West Nile Virus Infection - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BG-323 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CEL-1000 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ETX-112 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

FDX-000 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

HBV-002 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

HydroVax-001 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

interferon alfa-n3 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

KIN-1148 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MTX-113 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

rintatolimod - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit Flavivirus Serine Protease for Viral Infections - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit NS2B-NS3 Protease for Dengue, West Nile Virus and Zika Infections - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit NS5 for Japanese Encephalitis and Viral Infections - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Tatbeclin-1 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

West Nile virus vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

WNV-86 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

West Nile Virus Infections - Dormant Projects

West Nile Virus Infections - Product Development Milestones

Featured News & Press Releases

Nov 20, 2018: Vanderbilt discovery could neutralize West Nile virus

Feb 21, 2017: hVIVO notes the initiation of a Phase I clinical trial with AGS-v, a mosquito-borne disease vaccine candidate

Jul 06, 2015: NIH-funded vaccine for West Nile Virus enters human clinical trials

May 05, 2014: Alferon N Effective Against MERS Virus In-Vitro

Sep 12, 2013: Hemispherx Announces Initial Test Results in Biosecurity/Biodefense Arena

Sep 06, 2011: Hemispherx Enters Into Strategic Alliance With Armada Health Care For Alferon N Injection

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List Of Tables

LIST OF TABLES

- Table 1: Number of Products under Development for West Nile Virus Infections, H2 2019
- Table 2: Number of Products under Development by Companies, H2 2019
- Table 3: Number of Products under Development by Universities/Institutes, H2 2019
- Table 4: Products under Development by Companies, H2 2019
- Table 5: Products under Development by Universities/Institutes, H2 2019
- Table 6: Number of Products by Stage and Target, H2 2019
- Table 7: Number of Products by Stage and Mechanism of Action, H2 2019
- Table 8: Number of Products by Stage and Route of Administration, H2 2019
- Table 9: Number of Products by Stage and Molecule Type, H2 2019
- Table 10: West Nile Virus Infections - Pipeline by AIM ImmunoTech Inc, H2 2019
- Table 11: West Nile Virus Infections - Pipeline by CEL-SCI Corp, H2 2019
- Table 12: West Nile Virus Infections - Pipeline by Emergex Vaccines Ltd, H2 2019
- Table 13: West Nile Virus Infections - Pipeline by Ennaid Therapeutics LLC, H2 2019
- Table 14: West Nile Virus Infections - Pipeline by Fab'entech SA, H2 2019
- Table 15: West Nile Virus Infections - Pipeline by Hawaii Biotech Inc, H2 2019
- Table 16: West Nile Virus Infections - Pipeline by Imutex Ltd, H2 2019
- Table 17: West Nile Virus Infections - Pipeline by Kineta Inc, H2 2019
- Table 18: West Nile Virus Infections - Pipeline by Najit Technologies Inc, H2 2019
- Table 19: West Nile Virus Infections - Pipeline by Plex Pharmaceuticals Inc, H2 2019
- Table 20: West Nile Virus Infections - Dormant Projects, H2 2019
- Table 21: West Nile Virus Infections - Dormant Projects, H2 2019 (Contd..1), H2 2019

List Of Figures

LIST OF FIGURES

Figure 1: Number of Products under Development for West Nile Virus Infections, H2 2019

Figure 2: Number of Products under Development by Companies, H2 2019

Figure 3: Number of Products under Development by Universities/Institutes, H2 2019

Figure 4: Number of Products by Targets, H2 2019

Figure 5: Number of Products by Stage and Targets, H2 2019

Figure 6: Number of Products by Mechanism of Actions, H2 2019

Figure 7: Number of Products by Stage and Mechanism of Actions, H2 2019

Figure 8: Number of Products by Routes of Administration, H2 2019

Figure 9: Number of Products by Stage and Routes of Administration, H2 2019

Figure 10: Number of Products by Top 10 Molecule Types, H2 2019

Figure 11: Number of Products by Stage and Top 10 Molecule Types, H2 2019

COMPANIES MENTIONED

AIM ImmunoTech Inc

CEL-SCI Corp

Emergex Vaccines Ltd

Ennaid Therapeutics LLC

Fab'entech SA

Hawaii Biotech Inc

Imutex Ltd

Kineta Inc

Najit Technologies Inc

Plex Pharmaceuticals Inc

I would like to order

Product name: West Nile Virus Infections - Pipeline Review, H2 2019

Product link: <https://marketpublishers.com/r/W7AE4BADEA8EN.html>

Price: US\$ 2,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/W7AE4BADEA8EN.html>